

Adherium Partners with Rimidi to Revolutionise Respiratory Clinical Management Solutions

Highlights:

- Adherium secures strategic partnership secured with Rimidi, to optimise clinical workflows and enhance patient outcomes.
- Incorporating Adherium's Hailie® Smartinhalers® into Rimidi's platform will provide healthcare providers with real-time data on patients' medication adherence, inhaler technique, and respiratory health
- Partnership marks significant milestone in Adherium's focused sales, distribution and broader market engagement program in the US

Melbourne, Australia, 3 April 2024 — Adherium Limited (ASX: ADR), a global leader in respiratory digital health solutions, proudly announces a strategic partnership with [Rimidi](#), a leading clinical management platform designed to optimise clinical workflows, enhance patient experiences, and achieve quality objectives for chronic disease management.

This partnership marks a significant leap forward in Adherium's mission to extend its impact within the healthcare landscape, particularly in optimising clinical workflows and enhancing patient outcomes.

The collaboration will focus on integrating Adherium's innovative Hailie® Smartinhalers® into Rimidi's comprehensive clinical management platform now used by health systems, capitated health plans and physician practices across 17 states in the U.S. Rimidi's platform is renowned for its ability to seamlessly integrate within existing Electronic Health Record (EHR) workflows, supporting quality improvement initiatives, workflow optimisation, and patient engagement objectives including Epic and Cerner, the two EHR systems most widely used by U.S. hospitals and health systems.



ASX Release

By incorporating Adherium's Hailie® Smartinhalers® into Rimidi's platform, healthcare providers in all major health systems that use Epic and Cerner will be able to access real-time data on patients' medication adherence, inhaler technique, and respiratory health. This integrated approach empowers clinicians to make informed decisions, tailor interventions, and personalise care plans to improve patient outcomes effectively.

Dr. Paul Mastoridis, CEO of Adherium, expressed enthusiasm about the collaboration, stating, "Partnering with Rimidi aligns perfectly with our commitment to leveraging technology to advance respiratory care practices. Together, we aim to optimise clinical workflows and drive better outcomes for patients."

Rimidi's CEO, Lucienne Ide, echoed this sentiment, emphasising the potential of the partnership to revolutionise healthcare delivery. "We are excited to join forces with Adherium to incorporate the impressive Hailie® Smartinhaler® technology into our platform and offer a holistic solution that addresses the evolving needs of healthcare providers and patients alike. By combining our clinical management platform with Adherium's cutting-edge technology, we are poised to make a significant impact on the healthcare landscape."

The first implementations of this integrated solution will occur at a large health system in the U.S. Midwest and with capitated health plans in various parts of the United States.

Through this partnership, Adherium and Rimidi are set to redefine standards in clinical management solutions, empowering healthcare providers to deliver superior care, enhance patient engagement, and ultimately, transform healthcare delivery for the better.

-ENDS-



ASX Release

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Dr. Paul Mastoridis
Adherium Limited
Chief Executive Officer
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK
Director
haley@hck.digital

About Adherium (ASX: ADR)

Adherium Limited (ASX: ADR) is at the forefront of digital health technology, revolutionising patient care with its innovative remote monitoring and data-driven solutions. The company's flagship Hailie® system is redefining the management of chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). By enhancing medication adherence and promoting self-management, Hailie® is pivotal in improving patient health outcomes. Furthermore, it facilitates remote patient monitoring, enabling healthcare professionals to deliver quality care remotely—a service for which they can now be compensated. This advanced approach not only optimises health outcomes but also significantly reduces healthcare costs by minimising hospital admissions. With its clinically validated sensors, intuitive application, and robust data analytics platform, Adherium offers personalised, real-time insights for both patients and clinicians. Building on this, the company is expanding its market footprint in the United States and globally by forging strategic partnerships with leading hospital systems, medical groups, and insurance providers. Discover more about Adherium's mission to transform digital healthcare.



ASX Release

About Rimidi

Created by doctors, for doctors, Rimidi is a digital health company that supports healthcare providers in the delivery of remote patient monitoring and chronic disease management with EHR-integrated software, services, and connected devices. By combining clinical data from the EHR with data from connected devices and patient surveys, Rimidi presents a complete picture of the patient and supports care delivery across the continuum from the clinic to the home to allow for proactive, guideline-based management and prioritisation of highest-need patients. For more information, visit rimidi.com.